Efficacy and safety of combined nebulization of unfractionated heparin, acetylcysteine, budesonide and ipratropium bromide in hospitalised patients with COVID-19 pneumonia: a randomized controlled clinical trial

Efficacy and safety of combined nebulization of unfractionated heparin, acetylcysteine, budesonide and ipratropium bromide in hospitalised patients with COVID-19 pneumonia: a randomized controlled clinical trial

Abstract Background Promoting the absorption of COVID-19 pneumonia is critical for reducing pulmonary sequelae and improving prognosis. This study aimed to evaluate the efficacy and safety of nebulized unfractionated heparin, acetylcysteine, budesonide, and ipratropium bromide (HABIT) in hospitalize...

Full description

Saved in:
Bibliographic Details
Main Authors: Junhui Gong, Naifu Nie, Minrui Jiang, Xinyu Yang, Qinghua Wang, Jia Deng, Jun Kang, Xin Li, Li Zhang, Ying Zhang, Nuo Luo, Xiaoyi Du, Ling Wang, Wei Zhou, Hui Cao, Kunlin Li, Guoqiang Cao, Li Li
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Pulmonary Medicine
Subjects:
Corona virus disease 2019 (COVID-19)
Viral pneumonia
Pathophysiology
Nebulization therapy
Unfractionated heparin
CT severity scores
Online Access:https://doi.org/10.1186/s12890-025-03824-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12890-025-03824-5

Similar Items